You are here

Content

Publications

Original Articles, Letters & Editorials

1995

Heiss MM, Babic R, Allgayer H, Gruetzner U, Jauch KW, Loehrs U, Schildberg FW: Tumour associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase- type plasminogen activator system. Journal of Clinical Oncology, Vol. 13, No. 8, pp. 2084 - 2093, 1995.

Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Individual development and uPA-receptor-expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nature Medicine, Vol. 1, No.10, pp.1035-1039, 1995 (The contents of this paper were parts of H.A.’s thesis).

1996

Heiss MM, Babic R, Allgayer H, Grützner KU, Jauch KW, Löhrs U, Schildberg FW: The Prognostic Impact of the Urokinase-Type Plasminogen Activator System is Associated with Tumour Differentiation in Gastric Cancer. Eur J Surg Onc, Vol. 22, pp.74 - 77, 1996.

Heiss MM, Tarabichi A, Delanoff C, Allgayer H, Jauch KW, Hernandez-Richter T, Mempel W, Beck KG, Schildberg FW, Messmer K: Perisurgical erythropoietin application in anemic colorectal cancer patients: A double-blind randomized study. Surgery, 119: 523 - 527, 1996.

Heiss MM; Kaden AH, Allgayer H, Piltz S, Jauch KW, Schildberg FW: Prognoseverbesserung durch Metastasenresektion beim malignen Melanom (Prognostic influence of metastases resection in malignant melanoma). Akt Chir 31:294-297, 1996.

1997

Heiss MM, Allgayer H, Gruetzner KU, Tarabichi A, Mempel W, Jauch KW, Schildberg FW: Evidence for a blood transfusion effect on minimal residual disease in resected cancer patients. Anticancer Research, 17: 2657 - 2662, 1997.

Heiss MM, Fasol-Merten K, Allgayer H, Ströhlein MA, Tarabichi A, Wallner S, Eissner HJ, Jauch KW, Schildberg FW: Influence of autologous versus allogeneic blood transfusion on NK cell and LAK cell activities in cancer surgery. Vox Sanguinis 73: 237- 245, 1997.

Heiss MM, Fraunberger P, Delanoff C, Stets R, Allgayer H, Ströhlein MA, Tarabichi A, Faist E, Jauch KW, Schildberg FW: Modulation of immune response by blood transfusion: Evidence for a differential effect of allogeneic or autologous blood in colorectal cancer surgery. Shock 8:402-408, 1997.

Allgayer H, Heiss MM, Riesenberg R, Babic R, Jauch KW, Schildberg FW: Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA- R and CK18: Investigation of sensitivity, specificity and reproducibility of an immunogold/alcaline phosphatase double-staining protocol. J Histochem Cytochem 45(2): 203-212, 1997.

Allgayer H, Heiss MM, Riesenberg R, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW: Urokinase plasminogen activator receptor (uPA-R) - a potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Research 57: 1394 - 1399, 1997.

Allgayer H, Babic R, Grützner KU, Beyer BCM, Tarabichi A, Schildberg FW, Heiss MM: Immunohistochemical assessment of Cathepsin D in gastric cancer: Impact on clinical prognosis. Cancer 80: 179 - 187, 1997.

Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Loehrs U, Schildberg FW: Clinical value of an extended biological staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Annals of Surgery 226 (6): 736 – 745, 1997.

1998

Allgayer H, Babic R, Beyer BCM, Grützner KU, Tarabichi A, Schildberg FW, Heiss MM: Prognostic relevance of MMP-2 (72 kD-collagenase IV) in gastric cancer. Oncology 55:152 - 160, 1998.

Allgayer H, Babic R, Grützner KU, Beyer BCM, Tarabichi A, Schildberg FW, Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer: Analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16: 62 - 73, 1998.

Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D: Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signaling molecule. Oncogene 17:213 – 225, 1998.

1999

Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O, Boyd D: Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein 2alpha related factor. Journal of Biological Chemistry 274 (8): 4702 – 4714, 1999.

Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD: Transcriptional induction of the urokinase-receptor (u-PAR) gene by a constitutively active Src: Requirement of an upstream motif (-152/-135) bound with Sp1. Journal of Biological Chemistry 274 (26), 18428 – 18437, 1999.

Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D: Targeted disruption of the K- Ras oncogene in an invasive colon cancer cell line downregulates urokinase receptor expression and plasminogen- dependent proteolysis. British Journal of Cancer 80, 1884, 1999.

Dang J, Boyd D, Wang H, Allgayer H, Doe W, Wang Y: A region between –141 and – 61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase- type plasminogen activator receptor. European Journal of Biochemistry 264(1): 92-9, 1999.

2000

Allgayer H, Babic R, Grützner KU, Tarabichi A, Schildberg FW, Heiss MM: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. The Journal of Clinical Oncology 18(11): 2201 – 2209, 2000.

Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D: Identification of a novel nuclear factor- kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. European Journal of Biochemistry 267(11):3248-3254, 2000.

Heiss MM, Allgayer H, Funke I, Schildberg, FW: Disseminierte Tumorzellen als Prognosefaktor noch kontrovers. Diskussionsbeitrag zu Izbicki et al., Minimal residuale Tumorerkrankung bei soliden epithelialen Tumoren, Dt. Ärzteblatt 22/2000. Deutsches Ärzteblatt 51/52: 2953 – 2954, 2000.

2001

Allgayer H, Heiss MM: Fazit zu: Die minimal residuale Tumorerkrankung bei soliden Tumoren: Kritische Analyse des aktuellen Status quo. MMW Fortschritte der Medizin 4: 38, 2001.

Allgayer H, Heiss MM: Die minimal residuale Tumorerkrankung bei soliden Tumoren. Fortschr Med Orig 119(1):1-4, 2001.

Lengyel ER, Ried S, Heiss MM, Jäger C, Schmitt M, and Allgayer H: Ras-regulation of urokinase-type plasminogen activator. Methods in Enzymology 333 (G): pp.105-116, 2001.

2002

Allgayer H, Boyd DD, Heiss MM, Curley SA, Gallick GE: Elevated Src kinase activity in primary colorectal cancer is a biological indicator of poor clinical prognosis. Cancer 94: 344 – 351, 2002.

Heiss MM, Simon EH, Beyer BCM, Grützner KU, Tarabichi A, Babic R, Schildberg FW, and Allgayer H: Minimal residual disease in gastric cancer: First evidence of an independent prognostic relevance of urokinase receptor gene expression by disseminated tumor cells in a large series of patients. The Journal of Clinical Oncology 20(8): 2005-2016, 2002.

2003

Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, and Allgayer H: Tumor-specific transcription factor binding to an AP-2/Sp1 promoter element of the urokinase-receptor (u-PAR) promoter in a first large series of resected gastrointestinal cancers. Clinical Cancer Research 9(6): 2267-76, 2003.

Leupold JH, Colburn NH, Yang HS, Boyd DD, Lengyel ER, Jauch KW, und Allgayer H: Erster Hinweis auf eine Rolle des neu beschriebenenen Tumor –Suppressorgens Pdcd4 als Regulator des Invasionsmoleküls Urokinase Rezeptor. Langenbecks Arch Surg 2003.

Allgayer H: Molecular staging of cancer (invited Editorial). J Surg Oncology 82 (4), 217-223, 2003.

Allgayer H: Molekulare Regulation der Invasion von Tumorzellen—Ausgangspunkt für neues Tumor- Staging und eventuell neue Therapieansätze (Eingeladener Letter). Münchner Ärztliche Anzeigen 91(9): 3-4, 2003.

Allgayer H: Bericht zur Reise anlässlich der 103. Jahrestagung der Japanischen Gesellschaft für Chirurgie, Juni 2003, Sapporo (Eingeladener Bericht). Mitteilungen der Deutschen Gesellschaft für Chirurgie 4/2003, pp. 431-43.

2004

Htun van der Horst E, Leupold JH, Schubbert R, Ullrich A, and Allgayer H: TaqMan® based quantification of invasive cells in the chicken embryo metastasis assay. BioTechniques 37 (6): 940- 946, 2004.

Schewe DM, Biller T, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, und Allgayer H: Tumorspezifische Transkriptionsfaktorbindung an den Urokinase- Rezeptor-Promotor. Editorial Rubrik „gastrointestinale Tumore“, Kongresszeitung, Kongress Deutsche Gesellschaft für Chirurgie, 30.4.2004, Kaden-Verlag, S. 14.

2005

Allgayer H: Institut für molekulare Onkologie(IFOM) und Abteilung Molekulare Genetik am DIBIT-San Raffaele Institut in Milano, Italien—Bericht über einen Forschungsaufenthalt gefördert durch die Sektion Chirurgische Forschung/CAMO. Mitteilungen der Deutschen Gesellschaft für Chirurgie 4/05, pp. 391-392, 2005.

Allgayer H: Etablierung und Führung einer Gewebebank. Leitthema, Der Onkologe Suppl 1(11); p. S7- S11, 2005.

Schewe DM, Biller T, Maurer G, Leupold JH, Lengyel ER, Post S, and Allgayer H: Combination analysis of AP-1 family members, Sp1 and an AP-2α-related factor binding to different regions of the urokinase receptor (u-PAR) gene in a large series of resected gastrointestinal cancers. Clin Cancer Res 11(24): 8538-8548, 2005.

2006

Beyer BCM, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, and Allgayer H: Urokinase-system expression in gastric cancer – Confirmation of prognostic impact in an independent patient series and first evidence for a predictor in preoperative biopsies and intestinal metaplasia. Cancer 1: 106(1): 1026-1035, 2006.

Allgayer H, Manegold C, Grobholz R: Establishing a Tumor Tissue Bank—an Interdisciplinary Challenge. Am J Cancer 5(2): 93-98, 2006.

Allgayer H, Position Paper: Molecular regulation of an invasion-related molecule – options for tumor staging and clinical strategies. Eur J Cancer 42:7, 811-819, 2006.

Wang H, Yan Ch. Asangani I, Allgayer H, Boyd DD: Identification of an histone H3 acetylated/K9- methylated-bound intragenic enhancer regulatory for constitutive and phorbol ester -inducible urokinase receptor expression. Oncogene 1-13, 2006.

2007

Leupold JH, Yang H-S, Colburn NH, Boyd, DD, Lengyel ER, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (uPAR) gene expression via Sp-transcription factors. Oncogene 26(319): 4550-4562, 2007.

Leupold JH, Asangani I, Lengyel ER, Post S, Allgayer H: Src-induced uPAR gene expression is also mediated via an AP-1 motif and is associated with increased invasive capacity in vivo. Molecular Cancer Research 5(5):485-496, 2007.

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung H-M, Lau-Werner U, Post S, Allgayer H: First analysis of specific transcriptional regulators as predictors of independent prognostic relevance in resected colorectal cancer. Clinical Cancer Research 13(4): 1123-1132, 2007.

Mudduluru G, Medved F, Grobholz R, Joste C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition, correlates inversely with pAkt, and is a new and independent prognostic factor in resected colorectal cancer. Cancer 110:8, 1697-1707, 2007.

Schumacher J, Allgayer H: Comparative genomics on the basal mammalian urokinase receptor- promoter and impact for potential in vivo/clinical relevance in cancer. Advances in Gene, Molecular and Cell Therapy 1(1): 1-9, 2007.

Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, Gretz N: Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer. Nov 19; 97(10):1432-40, 2007.

2008

Bleier S, Maier P, Allgayer H, Wenz F, Zeller WJ, Frühauf S, Laufs S: Multiple displacement amplification enables large scale clonal analysis after retroviral gene therapy. J Virology 82(5), 2448-2455, 2008.

Asangani IA, Rasheed SAK, Leupold JH, Post S, Allgayer H: NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1(CAPNS1)gene. Gene 410(1):197-206, 2008.

Asangani IA, Rasheed SAK, Nikolova D, Leupold JH, Colburn NH, Post S, Allgayer H: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis. Oncogene, 3; 27(15):2128- 36, 2008 (Most cited original article Oncogene 2009, currently >3000 citations).

Mudduluru G, Allgayer H: The human receptor tyrosine kinase Axl gene – promoter characterization and regulation of constitutive expression by Sp1, Sp3, and CpG methylation. Bioscience Reports 28:161-175, 2008.

2009

Nikolova D, Asangani I, Nelson L, Hughes D, Siwak D, Mills G, Harms A, Buchholz E, Pilz L, Manegold C, Allgayer H: Cetuximab attenuates invasion, metastasis, and u- PAR gene expression in non-small-cell lung cancer (NSCLC), and u-PAR, besides E- cadherin, is a novel biomarker of Cetuximab sensitivity. Cancer Research 69(6):2461- 2670, 2009.

Appelt J-U, Giordano F, Ecker M, Roeder I, Grund N, Hotz-Wagenblatt A, Opelz G, Zeller J, Allgayer H, Fruehauf S, Laufs S: QuickMap: A public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Therapy 16(7):885-893, 2009.

Bürgy D, Weber T, Maurer G, Leupold JH, Mudduluru G, Medved F, Brauckhoff M, Post S, Dralle H, Allgayer H: Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenomas, and carcinoma in thyroid malignancies. International Journal of Cancer 125: 894-901, 2009.

Bürgy D, Kambakamba P, Fuchs T, Tang Y, Maurer G, Mudduluru G, Post S, Nakada MT, Yan L, Allgayer H: Prognostic impact of extracellular matrix metalloprotease inducer (EMMPRIN)- immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in the bone marrow of gastrointestinal cancer patients. Cancer 15: 4667-4678, 2009.

Wang Q, Sun Z-X, Allgayer H, Yang H-S: Down-regulation of E-cadherin is an essential event in activating ß-catenin/Tcf dependent transcription and expression of target genes in Pdcd4 knock-down cells. Oncogene 29(1):128-138, 2009.

Giordano F, Appelt J-U, Zucknick M, Abba M, Zeller WJ, Fruehauf S, Allgayer H, Laufs S: Cold spots in hot spots: transcription start sites of active genes are spared from HIV vector integration. AIDS  23(18):2535-7, 2009.

2010

Lichter P, Allgayer H, Bartsch H, Fusenig N, Hemminki K, von Knebel Doeberitz M, Kyewski B, Miller AB, zur Hausen H: Obligation for cell line authentication: appeal for concerted action. Int J Cancer 126(1):1, 2010.

Mudduluru G, Vajkoczy P, Allgayer H: Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 8(2): 159-169, 2010 (Highlight of the Issue).

Rasheed SAK, Efferth T, Asangani IA, Allgayer H: Artesunate – first evidence that an anti-malaria drug inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127(6):1475-85, 2010.

Ceppi P, Mudduluru G, Regalla K, Rap I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small-cell lung cancer. Mol Cancer Res Sept 8(9): 1207-16, 2010 (Highlight of the Issue).

Körner A, Mudduluru G, Manegold C, Allgayer H: Enzastaurin inhibits invasion and metastasis in lung cancer via diverse molecules. Brit J Cancer Sept 7, 103(6):802-11, 2010.

Grund N, Maier P, Giordano FA, Appelt JU, Zucknick M, Li L, Wenz F, Zeller WJ, Fruehauf S, Allgayer H, Laufs S: Analysis of lentiviral SIN vector integration sites and flanking gene expression in human peripheral blood progenitor cells following alkylator chemotherapy. Human Gene Therapy Aug 21(8):943-56, 2010.

Mudduluru G, Leupold JH, Stroebel P, Allgayer H: PMA up-regulates the transcription of Axl by AP-1 transcription factor binding to TRE sequences via the MAPK cascade in leukaemia cells. Biology of the Cell 103, 21-33, 2010.

2011

Jeltsch K, Radke T, Laufs S, Giordano F, Allgayer H, Wenz F, Zeller WJ, Kogler G, Maier P: USSC (unrestricted somatic stem cells): Interaction with CD34+ cells in vitro and in vivo – Expression of “homing genes” – Exclusion of tumorigenic potential. Cytotherapy Mar 13(3): 357-65, 2011.

Mudduluru G, Nesson George-William JN, Muppala S, Asangani IA, Regalla K, Nelson LD, Allgayer H: Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Bioscience Reports 31(3): 185-97, 2011 (Most cited original article contributing to impact factor of 2013).

Meseguer S, Mudduluru G, Escamilla JM, Allgayer H*, Barettino D*: Micro-RNAs- 10a and -10b contribute to retinoic acid-induced differentiation of neuroblastoma cells and target the alternative splicing regulatory factor SFRS1 (SF2/ASF). Journal of Biol Chemistry Feb 11 286(6):4150-64, 2011 (*shared senior authorship).

Mudduluru G, Ceppi P, Regalla K, Scagliotti GV, Papotti M, Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene, Jun 23;30(25):2888-99, 2011.

Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S, Roeder I, Kleff V, Zeller WJ, Allgayer H, von Kalle C, Fruehauf S, Moritz T, Laufs S: Clonal inventory screens uncover monoclonality following serial transplantation of MGMTP150K transduced stem cells and dose-intense chemotherapy. Human Gene Therapy, 2011.

Allgayer H, Hart IR: Editorial: Special Section “Site-Specific Metastasis”. Int J Cancer 128: 2509-2510, 2011.

Heckmann D, Laufs S, Maier P, Zucknick M, Giordano FA, Veldwijk MR, Eckstein V, Wenz F, Zeller JW, Fruehauf S, Allgayer H: A lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1 -induced migration and invasion. Onkologie 34:502-508, 2011.

2012

Regalla K, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J, Papotti M, Allgayer H: MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer J 2012 May 1;130(9):2044-53.

Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP: CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin- dependent adhesion. Cell Mol Life Sci. 2012 Feb;69(3):435-48.

Leupold JH, Asangani IA, Mudduluru G, Allgayer H: Promoter cloning and characterization of the human programmed cell death protein 5 (pdcd4) gene: Evidence for ZBP-89 and Sp binding motifs as essential Pdcd4-regulators. Bioscience Reports 32(3): 281-297, 2012.

Daidone MG, Foekens JA, Harbeck N, Martens J, Brunner N, Thomssen C, Hall JA, Salgado R, Dittmer J, Geurts-Moespot A, Duffy MJ, Sweep FCGJ, Schmitt M, EORTC PathoBiology Group (H. Allgayer Group Member): Identification, validation and clinical implementation of cancer biomarkers: Translational studies of the EORTC PathoBiology Group. Eur J Cancer 9, No. 2, 120-127, 2012.

Patil N, Abba M, Allgayer H: Cetuximab and biomarkers in non-small cell lung carcinoma. Biologics: Targets and Therapy 6:221-231, 2012.

Keklikoglou I, Koerner C, Schmidt C, Zhang JC, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A et al: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF- B and TGF-ß signaling pathways. Oncogene 2012 Sept 13;31(37):4150-63.

Nelson LD, Bender C, Mannsperger H, Buergy D, Kambakamba P, Palla S, Mudduluru G, Korf U, Hughes D, Van Dyke MW, Allgayer H: First analysis of the association of G*G multiplex nucleic acid-binding proteins with clinical outcome and proteomic changes in colorectal cancer. Molecular Cancer 2012 Jun 8;11(1):38.

Patil N, Abba M, Hödl P, Schwarzbach M, Allgayer H: A real time PCR based approach for the quantitative detection of FUS-CHOP fusion transcripts in human liposarcoma. Advances in Medical Sciences 57(1): 37-45, 2012.

Maier P, Heckmann D, Spier I, Laufs S, Zucknick M, Allgayer H, Fruehauf S, Zeller WJ, Wenz F: F2A sequence linking MGMTp140K and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells. Cancer Gene Therapy 1-9, 2012.

Abba M, Laufs S, Aghajany M, Wu H, Korn B, Benner A, Allgayer H: Look who’s talking: decoding differentially regulated epithelial and stromal pathways in colorectal cancer. Cancer Genomics & Proteomics 9: 15-26, 2012.

2013

Muppala S, Mudduluru G, Leupold JH, Buergy D, Sleeman JP, Allgayer H: CD24 induces expression of the oncomir miR-21 via Src, and CD24 and Src are both post- transcriptionally downregulated by the tumor suppressor miR-34a. PLOS ONE, Vol 8, March 2013 e5956.

Abba M, Patil N, Rasheed K, Nelson LD, Mudduluru G, Leupold JH, Allgayer H: Unraveling the role of FOXQ1 in colorectal cancer. Mol Cancer Res. 2013 Sept; 11(9):1017-28 (Highlight of the Issue).

Heckmann D, Maier P, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Allgayer H: CXCR4 expression and treatment with SDF-1α or Plerixafor modulate proliferation and chemosensitivity of colon cancer cells. Translational Oncology 6 (2): 124-132, 2013.

Schildberg C, Abba M, Merkel S, Agaimy A, Dimmler A, Schlabrakowski A, Croner C, Leupold JH, Hohenberger W, Allgayer H: COX-2, TFF1, and Src define better prognosis in young patients with gastric cancer. J Surg Oncol 2013 Nov (108(6): 409- 13.

Moreno-Mateos M, Barragán V, Torres B, Mudduluru G, Allgayer H, Pintor-Toro J: A novel method for the generation of small RNA expression libraries uncovers hsa-miR- 30b and hsa-miR-30c as key factors in anoikis resistance. RNA 2013 Dec; 19(12): 1711- 25.

Allgayer H: ADAM and EMMPRIN: a promising couple for more prognostic precision in patients with gastric cancer. Translational Gastrointestinal Cancer 2013; 2(S1): 83- 85 2014.

2014

Heckmann D, Maier P, Laufs S, Li L, Wenz F, Zeller WJ, Fruehauf S, Allgayer H: The disparate twins: A comparative study of CXCR4 and CXCR7 in SDF-1-induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res. 2014 Feb 1;20(3):604-16. doi: 10.1158/1078-0432.CCR-13-0582. Epub 2013 Nov 19.

Patil N, Rasheed SAK, Abba M, Leupold JH, Schwarzbach M, Allgayer H: A mechanistic study on the metastasis inducing function of FUS-CHOP fusion protein in liposarcoma Running title: The role of FUS- CHOP in metastasis. Int J Cancer. 2014 Jun 15;134(12):2808-19.

Schildberg C, Abba A, Merkel S, Agaimy A, Dimmler A, Schlabrakowski A, Croner C, Leupold JH, Hohenberger W, Allgayer H: Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations. Adv Med Sci. 2014 Mar;59(1):142-6.

Rotert JV, Hohenberger P, Nowak K, Leupold JH, Allgayer H: Src activity is increased in gastrointestinal stromal tumors — analysis of associations with clinical and other molecular tumor characteristics. Journal of Surgical Oncology 2014, May; 109(6):597- 605.

Schmaus A, Klusmeier S, Rothley M, Dimmler A, Sipos B, Faller G, Thiele W, Allgayer H, Hohenberger P, Post S, Sleeman JP: Accumulation of small hyaluronan oligosaccharides in tumour intestinal fluid correlates with lymphatic invasion and lymph node metastasis. Br J Cancer, 2014, Jul 29; 111(3):559-67.

2015

Oleksiuk O, Abba M, Tezcan K, Schauffler W, Bestvater F, Patil N, Birk U, Hafner M, Altevogt P, Cremer C, Allgayer H: Single- Molecule Localization Microscopy allows for the analysis of cancer metastasis-related miRNA distribution on the nanoscale. Oncotarget, 29 Dec, 6(42):44745-57, 2015.

Mudduluru G*, Abba M* (* shared first authors), Batliner J*,Patil N, Scharp M, Leupold JH, Oleksiuk O, Buchhalter I, Thiele W, Benner A, Sleeman J, Allgayer H: A systematic approach to defining the microRNA landscape in metastasis. Cancer Res, Aug 1;75(15):3010-9, 2015.

Feng T, Dzieran, Gu X, Marhenke S, Vogel A, Machida K. Weiss TS, Rümmele P, Kollmar O, Hoffmann P, Graesser F, Allgayer H, Fabian J, Weng HL, Teufel A, Maass T, Meyer , Lehmann U, Zhu C, Mertens PR, Gao CF, Dooley S, Meindl-Beinker NM: Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clinical Science, Jun;128(11):761-74, 2015.

Fernández-Ulibarri I, Hammer K, Arndt MA, Kaufmann JK, Dorer D, Engelhardt S, Kontermann RE, Hess J, Allgayer H, Krauss J, Nettelbeck DM: Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer 136(9):2228-40, 2015.

Abba M, Benner A, Patil N, Heil O, Allgayer H: Differentially expressed microRNAs in colorectal cancer metastasis; Genomics Data 2015, 6:33–35. doi: 10.1016/j.gdata.2015.08.001.

Abba M, Patil N, Leupold JH, Allgayer H: MicroRNAs-From Metastasis Prediction to Metastasis Prevention. Mol Cell Oncol 2016 Mar; 3(2): e1074336. doi: 10.1080/23723556.2015.1074336.

2016

Bohländer PR, Abba ML, Bestvater F, Allgayer H, Wagenknecht HA: Two wavelength-shifting molecular beacons for simultaneous and selective imaging of vesicular miRNA-21 and miRNA-31 in living cancer cells. Org Biomol Chem 2016;14(22):5001-6. doi: 10.1039/c6ob00691d.

El-Daly SM, Abba ML, Patil N, Allgayer H: miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. Nature Scientific Reports 2016 Apr 20;6:24720. DOI: 10.1038/srep24720.

Cremers N, Neeb A, Uhle T, Dimmler A, Rothley M, Allgayer H, Fodde R, Sleeman JP, Thiele W: CD24 Is Not Required for Tumor Initiation and Growth in Murine Breast and Prostate Cancer Models. PLoS One 2016 Mar 15;11(3):e0151468. Doi: 10.1371/journal.pone.0151468.

Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, Beckers A, Preter K, Decock A, Patil N, Abba M, Kopp-Schneider A, Astrahantseff K, Wünschel J, Pfeil S, Ercu M, Künkele A, Hu J, Thole T, Schweizer L, Mechtersheimer G, Carter D, Cheung BB, Popanda O, Deimling AV, Koster J, Versteeg R, Schwab M, Marshall GM, Speleman F, Erb U, Zoeller M, Allgayer H, Simon T, Fischer M, Kulozik AE, Eggert A, Witt O, Schulte JH, Deubzer HE: MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget 2016 Aug 27. DOI: 10.18632/oncotarget.11662 (Priority Paper).

2017

Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min LF, Zhang XW, Jia QQ, Yu J, Yang JQ, Allgayer H, Abba ML, Zhang XZ, Sun XC: What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget. 2017 Jun 28;8(51):89095-89107. doi: 10.18632/oncotarget.18760. PMID: 29179502; PMCID: PMC5687672.

Laudato S, Patil N, Abba ML, Leupold JH, Benner A, Gaiser T, Marx A, Allgayer H: P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017 Nov 1;141(9):1879-1890.  doi: 10.1002/ijc.30854. Epub 2017 Jul 24. PMID: 28656629.

Niklinski J, Kretowski A, Moniuszko M, Reszec J, Michalska-Falkowska A, Niemira M, Ciborowski M, Charkiewicz R, Jurgilewicz D, Kozlowski M, Ramlau R, Piwkowski C, Kwasniewski M, Kaczmarek M, Ciereszko A, Wasniewski T, Mroz R, Naumnik W, Sierko E, Paczkowska M, Kisluk J, Sulewska A, Cybulski A, Mariak Z, Kedra B, Szamatowicz J, Kurzawa P, Minarowski L, Charkiewicz AE, Mroczko B, Malyszko J, Manegold C, Pilz L, Allgayer H, Abba ML, Juhl H, Koch F: MOBIT Study Group: Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project. Adv. Med Sci. 2017 Jun 21;62(2):405-413. doi: 10.1016/j.advms.2017.05.002. PubMed PMID: 28646744.

2018

Ishaque N, Abba ML, Hauser C, Patil N, Paramasivam N, Huebschmann D, Leupold JH, Balasubramanian GP, Kleinheinz K, Toprak UH, Hutter B, Benner A, Shavinskaya A, Zhou C, Gu Z, Kerssemakers J, Marx A, Moniuszko M, Kozlowski M, Reszec J, Niklinski J, Eils J, Schlesner M, Eils R, Brors B, and Allgayer H: Whole genome sequencing reveals novel hypotheses on metastasis evolution and therapy in colorectal cancer. Nature Communications 2018, Nov 14;9(1):4782. doi: 10.1038/s41467-018- 07041-z.

Klingenberg M, Groß M, Goyal A, Polycarpou-Schwarz M, Miersch T, Ernst AS, Leupold J, Patil N, Warnken U, Allgayer H, Longerich T, Schirmacher P, Boutros M, Diederichs S:The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling. Hepatology. 2018, Epub 2018 Oct 12. Nov;68(5):1817-1832. doi: 10.1002/hep.30102.

2019

Braun J, Pastene DO, Breedijk A, Rodriguez A, Hofmann BB, Sticht C, von Ochsenstein E, Allgayer H, Van den Born J, Bakker S, Hauske SJ,. Krämer BK, Yard BA, Albrecht T: Methylglyoxal down-regulates the expression of cell cycle associated genes and activates the p53 pathway in human umbilical vein endothelial cells. Nature Scientific Reports. 2019 Feb 4;9(1):1152. doi: 10.1038/s41598-018-37937-1.

Allgayer H (Editorial invited by Prof. Isaac P. Witz): Deciphering the “Metastasome” leads to novel hypotheses on understanding the evolution of metastasis and implicates consequences for metastasis therapy and prevention. Cancer Microenviron. 2019 Apr;12(1):1-2. doi: 10.1007/s12307-019-00221-5. PMID: 30815790

Marongiu L, Allgayer H. Mingle: A Command line utility for merging multi-fasta files. J Comput Biol. 2019 Apr;26(4):396-404. doi: 10.1089/cmb.2018.0243. Epub 2019 Feb 14. PMID: 30762421.

2020

Marongiu L, Shain E, Shain K, Allgayer H. Filtering maxRatio results with machine learning models increases quantitative PCR accuracy over the fit point method. J Microbiol Methods. 2020 Feb;169:105803. doi: 10.1016/j.mimet.2019.105803. Epub 2019 Dec 4. PMID: 31809831.

Gandhi M, Groß M, Holler JM, Coggins SA, Patil N, Leupold JH, Munschauer M, Schenone M, Hartigan CR, Allgayer H, Kim B, Diederichs S. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020 Jun 25;11(1):3214. doi: 10.1038/s41467-020-17007-9. PMID: 32587247; PMCID:PMC7316977.

Larribère L, Wibowo1 Y, Patil N, Abba M, Sachpekidis C, Tundidor Pérez1 I, Gerardo Aguiñón Olivares R, Allgayer H and Utikal J. NF1-RAC1 axis regulates migration of the melanocytic lineage. Translational Oncology. 2020 (Manuscript accepted).

Reviews, Book Chapters & Congress Proceedings

1994

Allgayer H, Heiss MM, Babic R, Grützner KU, Jauch KW, Schildberg FW: Definition funktioneller Risikofaktoren beim Magenkarzinom durch das Urokinase-System. In: Trede et al. (ed.): Chirurgisches Forum 1994 f. experim. und klinische Forschung, Springer-Verlag Berlin-Heidelberg, pp. 353-357, 1994.

Heiss MM, Allgayer H, Babic R, Grützner U, Jauch KW, Schildberg FW: Prognostic value of new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. In: Wangsteen O (ed.): American College of Surgeons, Surgical Forum, 80th Annual Clinical Congress, Vol. XLV, pp. 482-485, 1994

1995

Allgayer H, Heiss MM, Babic R, Löhrs U, Schildberg FW, Jauch KW: Functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. In: Nishi M, et al. (ed.): 1st Int Gastric Canc Congr, Kyoto, Japan, March 29 - April 1, 1995: pp. 427-430, Monduzzi Edi (Bologna), 1995.

1996

Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Schildberg FW: Differentielle Bedeutung des Urokinase-Systems für die Prognose des Magenkarzinoms. In: Trede et al. (ed.): Chirurgisches Forum 1996 f. experim. und klinische Forschung, Springer-Verlag Berlin-Heidelberg, pp. 377 – 381, 1996.

1997

Allgayer H, Heiss MM, Schildberg FW: Prognostic parameters in gastric cancer: Review. Brit J Surgery 84: 1651 - 1664, 1997.

Allgayer H, Heiss MM, Schildberg FW, et al.: Neue Prognosefaktoren beim gastrointestinalen Karzinom. In: Roder JD (Ed.): Tumormanual Gastrointestinale Tumoren des Tumorzentrums Muenchen 1997.

Heiss MM, Allgayer H, Babic R, Grützner KU, Löhrs U, Jauch KW, Schildberg FW: Funktionelles Staging des Magenkarzinoms – Eine neue Sichtweise durch Einbeziehung der früh- systemischen Komponente und tumor-assoziierter Proteolysesysteme. In Langenbecks Arch Chir Suppl II (Kongreßbericht). Springer Verlag Berlin-Heidelberg, pp. 1465-1466, 1997.

Heiss MM, Allgayer H, Grützner KU, Jauch KW, Schildberg FW: Proposal of a new biological staging model in gastric cancer considering biological grading and minimal residual tumor disease. In: Wangensteen OH (ed). Surgical Forum, 83rd Ann Clin Congr Chicago, pp. 845 - 848, 1997.

2000

Beyer BCM, Allgayer H, Pietsch AR, Heizmann O, Grützner KU, Schildberg FW, Heiss MM: Tumor-assoziierte Proteolyse und Prognose: Validierung der Bedeutung des Urokinase-Systems beim Magenkarzinom zum präoperativen Staging. In: Enke A, et al (Hrsg). Langenbecks Arch Chir, Chirurg Forum 2000 f experim u klin Forschung. Springer Verlag Berlin-Heidelberg, pp. 89-92, 2000.

Pietsch AR, Allgayer H, Beyer BCM, Grützner KU, Lau-Werner UM, Schildberg FW, Heiss MM: Minimal residuale Tumorerkrankung beim kolorektalen Karzinom: Prognostische Bedeutung des perioperativen Tumorzellnachweises und folgender Verlaufsuntersuchungen. In: Enke A, et al (Hrsg). Langenbecks Arch Chir, Chirurg Forum 2000 f experim u klin Forschung. Springer Verlag Berlin-Heidelberg, pp. 119- 121, 2000.

2001

Allgayer H, Lengyel ER, and Boyd D: Transcriptional regulation of proteases. (Eingeladener Beitrag) In: Muschel R (Ed.): Proteases and their inhibitors in cancer metastasis. Kluwer 2001.

Allgayer H, Heiss, MM: Die minimal residuale Tumorerkrankung. Prognostische Aussagekraft und therapeutische Konsequenz (Eingeladenes Review). Originalienband der Münchener Medizinischen Wochenschrift, IV/2000, pp.1-4, 2001.

Allgayer H, Boyd DD, Lengyel ER, Heiss MM: The urokinase-receptor – Molecular regulation and clinical significance. (Eingeladenes Review). Res Adv Cancer 1: pp.85- 97, 2001.

Allgayer, H, Heiss MM, Schildberg FW, et al.: Neue Prognosefaktoren beim gastrointestinalen Karzinom. In: Heiss MM (Ed.): Tumormanual Gastrointestinale Tumoren des Tumorzentrums Muenchen, Neuauflage 2001.

2002

Allgayer H: Erfassung einer potenziell minimal residualen Tumorerkrankung bei soliden Tumoren – Chancen und Grenzen (Eingeladenes Review). AKODH (Zeitschrift für naturheilkundliche Onkologie) 9: 6-10, 2002.

Heiss MM, Allgayer H: Kongressbericht: Molekulares Staging von Karzinomen. Deutsches Ärzteblatt 33: 1868 – 1870, 2002.

Heiss MM, Allgayer H: Molekulares Staging von Karzinomen. Onkologie 2002,25;371

2003

Allgayer H: Molecular regulation of urokinase-receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy. In: Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, pp. 15- 30, Springer Verlag (Berlin, Heidelberg, New York), 2003.

Allgayer H, Heiss MM, Schildberg FW: Summary and Congress Report: Molecular Staging of Cancer - Concepts of Today, Therapies of Tomorrow. In: Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, pp. 211-217, Springer Verlag (Berlin, Heidelberg, New York) 2003.

Fuchs T, and Allgayer H: Transcriptional regulation of the urokinase-receptor (invited review). Biol Chem. 384(5):755-61, 2003.

2005

Allgayer H, and Lengyel ER: Urokinase and its Receptor - Essential Players in Metastasis (invited review), Cell Cycle. 2006 Aug;5(16):1760-71. Epub 2006 Aug 15.

Allgayer H: Etablierung und Führung einer Tumorbank. In: Manegold, C (Hrsg): Therapieoptionen beim nicht-kleinzelligen Lungenkarzinom. UNI-MED Verlag AG, 2005, pp. 144-150.

Allgayer H, and Lengyel ER: Urokinase and its Receptor --- Essential Players in Metastasis, Ed. Rinker-Schaeffer C., Sokoloff M., Yamada, SD, Humana Press, 2005. (invited review).

2006

Allgayer H: Regulation and clinical significance of urokinase receptor (u-PAR), an invasion related molecule. Z. Gastroenterol 44: 1-9, 2006.

Laufs S, Schumacher J, Allgayer H: Urokinase receptor (u-PAR) – an essential player in multiple games of cancer. A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome, in minimal residual disease. (Invited Review). Cell Cycle (2006) 5(16):1760-71.

Allgayer H: Review on the EACR Young Cancer Researcher Award Lecture, ECCO 13-Meeting, 2005. EACR News Letter, European Association of Cancer Research, Nottingham/UK. EACR Newsletter 4 -5, 2006.

Kp Allgayer H: Clinical recommendations for diagnosis, treatment and follow-up of non- small cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma. CSC „Petro Ofsetas“, LT-Vilnius, 2006.

2007

Allgayer H: Ein Meilenstein translationaler Forschung. Kommentar zur Studie von Olaussen KA et al. Focus Onkologie 1-2:20-21, 2007.

Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE: Tumor-associated proteolytic factors uPA and PAI-1: Critical appraisal of their clinical relevance in breast cancer and their integration into decision- support algorithms. Crit Rev in Clin Lab Sciences 44(2):179-201, 2007.

Brandt B, Vogt U, Allgayer H: Neue molekulare Perspektiven. In: Schlotter CM, Bonk U (eds): Individualisierte Konzepte der primär systemischen und adjuvanten Therapie des Mammakarzinoms – Gen und Genexpression. UNIMED Verlag, 2007.

Allgayer H: Establishing a tumor tissue bank: An interdisciplinary challenge. In: Manegold, C (ed): Therapeutic options in non-small cell lung cancer. UNI-MED Verlag AG, 2007, pp 23-29.

Allgayer H: Die „customized therapy“ ist im Kommen. Kommentar zur Studie von Cobo et al. Focus Onkologie 12: 20-21, 2007.

2008

Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N: The urokinase- system – role of cell proliferation and apoptosis. Histol Histopathol 23:227-236, 2008.

Laufs S, Blier S, Maier P, Wenz F, Zeller J, Frühauf S, Allgayer H: Multiple displacement amplification enables large scale clonal analysis following retroviral gene therapy. J Virology 82(5): 2448-2455, 2008.

Allgayer H, Aguirre-Ghiso J.A.: The urokinase receptor (u-PAR) - a link between tumor cell dormancy and minimal residual disease in bone marrow? (Invited review in Honor of Judah Folkman). APMIS 116:602-14, 2008.

Allgayer H, Fulda S: An introduction to molecular targeted therapy. fabian s, 53, 2008.

Schlotter CM, Vogt U, Allgayer H, Brandt B: Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 10(4):211, 2008.

Allgayer H: General insights into tumor invasion, progression, and metastasis. In: Allgayer H, Rehder H, Fulda S (eds): Hereditary Tumors. Wiley Blackwell 2008, pp. 3-24.

Allgayer H, Fulda S: Molecular targeted therapy. In: Allgayer H, Rehder H, Fulda S (eds): Hereditary Tumors. Wiley Blackwell 2008, pp. 501-514.

2009

Abba M, Allgayer H: Micro-RNAs as regulatory molecules in cancer: A focus on models defining MiRNA functions. Drug Discovery Today: Disease Models, 2009.

Allgayer H: EGFR Genamplifikatoin: ein vielversprechender Marker. Kommentar zur Arbeit Hirsch FR et al. Fokus Onkologie, 1-2, 20-21.

Hildenbrand R., Schaaf A., Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P: Tumor stroma ist he predominent uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. Histol Histopathol 2009, 24: 869-877.

2010

Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev. Oncol/Hematol 73 (2010) 185-191 (Invited Review).

Allgayer H: Translational research on u-PAR. Eur J Cancer 46:1241-1251, 2010 (Invited Review for Dr. Patricia Steeg).

Hildenbrand R, Allgayer H, Marx A, Stroebel P: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs 19(5): 641-652, 2010.

2012

Abba M, Mudduluru G, Allgayer H: MicroRNAs in cancer: Small molecules, big chances. Anti-Cancer-Agents in Medicinal Chemistry. Vol 12., No. 7. pp. 733-743, 2012, (Invited Review).

Leupold JH and Allgayer H: Plasminogen Activators and Their Inhibitors in Cancer, in Matrix Proteases in Health and Disease (ed N. Behrendt), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2012 (Invited Book Chapter).

2014

Abba M, Patil N, Allgayer H (Invited review): MicroRNAs in the regulation of MMPs and metastasis. Cancer 6: 625-645, 2014.

2015

Utikal J, Abba M, Novak D, Moniuszko M, Allgayer H (Invited Review): Function and Significance of MicroRNAs in benign and malignant Human Stem Cells. Seminars in Cancer Biology, Dec 35:200-11, 2015.

Rusek AM, Abba M, Eliaszewicz A, Moniuszko M, Niklinski J, Allgayer H: MicroRNA modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer. Molecular Cancer, Feb 7; 14:34, 2015.

2016

Abba ML, Patil N, Leupold JH, Allgayer H: MicroRNA Regulation of Epithelial to Mesenchymal Transition. J Clin Med. 2016 Jan 14;5(1):8. doi: 10.3390/jcm5010008. PMID: 26784241; PMCID: PMC4730133.

2017

Abba ML, Patil N, Leupold JH, Moniuszko M, Utikal J, Niklinski J, Allgayer H (invited Review): MicroRNAs as novel targets and tools in cancer therapy. Cancer Lett. 2017;387:84-94. doi: 10.1016/j.canlet.2016.03.043.

2018

Lin Tu, Peter Hohenberger, Hui Cao, Allgayer H: Standard Approach to Gastrointestinal Stromal Tumors-Differences between China and Europe. 2018, Visc Med 2018;34:353–358. DOI: 10.1159/000494347. Epub 2018 Oct 19. PMID: 30498702; PMCID: PMC6257205.

Abba ML, Patil N, Leupold JH, Saeed MEM, Efferth T, Allgayer H (Invited Review): Prevention of carcinogenesis and metastasis by Artemisinin-type drugs. Cancer Lett. 2018 Aug 10; 429:11-18. doi: 10.1016/j.canlet.2018.05.008. Epub2018 May 8, PMID:29746932, DOI:10.1016/j.canlet.2018.05.008

2019

Allgayer H, Leupold JH, Patil N. Defining the "Metastasome": Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences (Invited Review). Semin Cancer Biol. 2019 Jul 27. pii: S1044- 579X(19)30156-7. doi: 10.1016/j.semcancer.2019.07.018. Review. PMID: 31362074

2020

Leupold JH, Patil N and Allgayer H. The chicken egg chorionallantois membrane (CAM) model as an in vivo method for the investigation of the invasion and metastasis cascade of malignant tumor cells. Tumor Microenvironment: Molecular Players – Part B. Editor: Prof Ulrike S. Stein. Springer 2020, in press.

Leupold JH., Patil N and Allgayer H. MicroRNAs in the tumor microenvironment. Tumor Microenvironment – Novel Concepts, The Springer Nature series "Advances in Experimental Medicine and Biology (ISSN:0065-2598)" 2020, in press

2019

Leupold JH, Patil N and Allgayer H. The chicken egg chorionallantois membrane (CAM) model as an in vivo method for the investigation of the invasion and metastasis cascade of malignant tumor cells. Tumor Microenvironment: Molecular Players – Part B. Editor- Prof Ulrike S. Stein. (Springer) 2019.

Allgayer H, Leupold JH, Patil N. Defining the "Metastasome": Perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences (Invited Review). Semin Cancer Biol., epub ahead of print 2019 Jul 27. pii: S1044-579X(19)30156-7. doi: 10.1016/j.semcancer.2019.07.018. Review. PMID: 31362074

Leupold JH., Patil N and Allgayer H. MicroRNAs in the tumor microenvironment. Tumor Microenvironment – Novel Concepts, The Springer Nature series "Advances in Experimental Medicine and Biology (ISSN:0065-2598

Books

2003

Allgayer H, Heiss MM, Schildberg FW (Eds.): Molecular Staging of Cancer. Rec Results Canc Res 162, ISBN 3-540-43469-0, Springer Verlag (Berlin, Heidelberg, New York) 2003.

2006

Allgayer H, Manegold C, Post S, Heiss MM, Poustka A, Wiestler O: Kongressband “Molecular Staging of Cancer“, European Journal of Cancer Vol. 4, No. 6, 2006.

2008

Allgayer H, Rehder H, Fulda S (eds.): Hereditary Tumors. Hereditary Tumors. From genes to clinical consequences. Wiley VCH, 2008.

2020

Bauer A, Hofheinz , Utikal J: Ethical Challenges in Cancer diagnosis and Therapy. Editor-in-Chief: Allgayer, H. Recent Results in Cancer, Springer Nature, in press

Abstracts & Cited Abstracts

1993

Heiss MM, Babic R, Allgayer H, Grützner KU, Löhrs U, Schildberg FW: Korrelation von klinischem Verlauf und immunhistochemischem Nachweis von Urokinase-Typ Plasminogenaktivator (u-PA), dem Rezeptor (u-PAR) und Inhibitor Typ 1 (PAI 1) an Magenkarzinomen. Verhandlungen der Deutschen Gesellschaft für Pathologie 77: 528, 1993.

1994

Heiss MM, Jauch KW, Gruetzner KU, Allgayer H, Funke I, Schildberg FW: Prognostic value and fate of bone-marrow micrometastasis in curatively resected gastric cancer patients. Pan-Pacific Surgical Association, 22nd Congress, 31.1. - 4.2.1994, Hong Kong, 1994.

Heiss MM, Allgayer H, Babic R, Grützner U, Jauch KW, Schildberg FW: Prognostic impact of urokinase- type plasminogen-activator system expression increases with tumor dedifferentiation in gastric cancer. Eur J Surg Oncol 20(3):361 – 362, 1994.

Allgayer H, Heiss MM, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW: Prognostic significance of uPA-receptor-expression by disseminated tumour cells. in: Benrad et al. (ed.): Clinical Applications of the plasminogen activator system in cancer. Finsen Laboratory, Copenhagen, p. 30, Nov. 1995.

HeissMM, Allgayer    H, Gruetzner KU, Schildberg FW, Jauch KW: Prognostischer Wert und Längsschnittverlauf von Mikrometastasen im Knochenmark beim resezierten Magenkarzinom. in: Hohenberger W, Wittekind C (ed.): Wertigkeit zytologischer Untersuchungen beim Staging solider Tumoren. Workshop Erlangen, p. 7, Dez. 1995.

Jauch KW, Heiss MM, Babic R, Allgayer H, Löhrs U, Schildberg FW: Functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. First Int Gastric Canc Congr, Kyoto, Japan, (Proceedings), p. 72, 1995.

Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Löhrs U, Schildberg FW: Expression of tumor - associated proteases and their inhibitors in gastric cancer: Impact on prognosis. AACR Proceedings 36, p. 93, 1995.

1996

Allgayer H, Heiss MM, Babic R, Gruetzner KU, Jauch KW, Schildberg FW: Expression of uPA-receptor on disseminated tumor cells in bone marrow - evidence for the metastatic phenotype in minimal residual tumor disease. Proceedings of the AACR Conference Proteases and Protease Inhibitors, Panama City, Florida, March 1996.

Heiss MM, Allgayer H, Grützner KU , Babic R, , Jauch KW, Löhrs U, Schildberg FW: Functional staging in gastric cancer - new aspects by bone marrow micrometastases and tumor-associated proteases. Eur J Surg Onc 22(4): 407, 1996.

Allgayer H, Heiss MM, Babic R, Jauch K-W., Schildberg FW: Expression des uPA- Rezeptors auf disseminierten Tumorzellen des Knochenmarks - erster Hinweis auf den metastatischen Phänotyp einer minimal residualen Tumorkomponente beim soliden Karzinom. Wissenschaftl. Referate, Vereinigung Bayerischen Chirurgen e.V., Würzburg, pp. 33, 1996.

Allgayer H, Grützner KU, Simon W, Babic R, Schildberg FW, Heiss MM: Urokinase- Rezeptor als Charakeristikum des metastatischen Phänotyps minimal residualer Tumorzellen beim soliden Karzinom. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, München, 275-276, 1996.

Beyer BCM, Babic R, Allgayer H, Grützner KU. Schildberg FW, Heiss MM: Neue funktionelle Prognosefaktoren des Magenkarzinoms - definiert durch tumorassoziierte Proteolysesysteme. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, München, pp. 276-277, 1996.

Heiss MM, Allgayer H, Grützner KU, Jauch KW, Schildberg FW: Prognostischer Wert und Längsschnittverlauf von Mikrometastasen im Knochenmark bei resezierten Magenkarzinom. In: Klein HG, Seidel D (eds). Research Festival 96, Klinikum Großhadern, München, 277-278, 1996.

1997

Heiss MM, Allgayer H, Grützner KU, Babic R, Jauch KW, Schildberg FW: Functional staging in gastric cancer - New aspects through bone marrow micrometastases and tumor-associated proteases. Int Symposium „Proteases and Cancer“ (Biomed-1 Meeting), Heidelberg, Abstract No. 6, 1997.

Heiss MM, Allgayer H, Jauch KW, Funke I, Gruetzner U, Schildberg FW: Neue Prognosefaktoren beim Magenkarzinom. Wissenschaftliche Ausstellung zum 114. Kongress der Deutschen Gesellschaft fuer Chirurgie in München, 1997.

Stroehlein MA, Fraunberger P, Stets R, Allgayer H, Tarabichi A, Delanoff C, Grützner KU, Wustrow T, Schildberg FW, Heiss MM: Blood transfusion effects on predominant Th1 or Th2 type helper cell response in cancer surgery. Proc Am Assoc Can Res, San Diego, USA 795:119, 1997.

1998

Allgayer H, Wang H, Boyd D: Regulation of the expression of the urokinase-type plasminogen activator gene by AP-2. AACR Proceedings 39: 492, 1998.

Allgayer H, Wang H, Boyd DD: Downregulation of urokinase-type plasminogen activator receptor (u- PAR) in a highly invasive colon cancer cell line made to express a dominant negativeAP-2 is mediated by a motif bound with an AP-2-like protein, Sp1 and Sp3 and is associated with reduced extracellular matrix degradation. Proceedings of the Metastasis Research Society, VII International Congress, Oct. 7-10, 1998, San Diego, Ca, USA, p. 34, 1998.

Beyer BCM, Allgayer H, Babic R, Grützner KU, Tarabichi A, Heiss MM, Schildberg FW: Die prognostische Bedeutung von MMP-2 beim Magenkarzinom, sowie ein therapeutischer Ansatz mit Marimastat beim inoperablen (lokal fortgeschrittenen bzw. metastasierten) Stadium. 4. Wissenschaftl. Seminar des Klinikums Großhaderns, Univ. Int. Di Venezia, Italien: 25, 1998.

Pietsch AR, Allgayer H, Grützner KU, Lau-Werner U, Heiss MM, Schildberg FW: Die prognostische Bedeutung disseminierter Tumorzellen beim colorektalen Karzinom: Perioperativer Nachweis und Längsschnittuntersuchung. 4. Wissenschaftl. Seminar des Klinikums Großhaderns, Univ. Int. Di Venezia, Italien: 26, 1998.

Heiss MM, Pietsch AR, Allgayer H, Grützner KU, Schildberg FW: Prognostic significance of disseminated tumour cells in colorectal cancer: Perioperative state and follow-up. Langenbeck Arch Surg 383,5:36, 1998.

1999

Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD: Transcriptional induction of the urokinase-receptor (u-PAR) gene by a constitutively active Src: Requirement of an upstream motif (-152/-135) bound with Sp1. AACR Proceedings 40, Abstract 1311, 1999.

Heiss MM, Babic R, Grützner KU, Tarabichi A, Schildberg FW, and Allgayer H: c- erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor - associated protease systems. Eur J Cancer 35 (Suppl. 5): 15, 1999.

Allgayer H, Wang H, Gallick GE, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Urokinase- receptor expression is transcriptionally induced by Src via an upstream element (-152/-135) bound with Sp1. Eur J Cancer 35 (Suppl. 5): 13, 1999.

Heiss MM, Babic R, Grützner KU, Tarabichi A, Schildberg FW, and Allgayer H: c- erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor - associated protease systems. Langenbeck´s Arch Surg 384 (5): 500, 1999.

Allgayer H, Wang H, Gallick GE, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Urokinase- receptor expression and proteolysis is transcriptionally induced by Src: A proposal for Src as a target for anti-invasive therapy in colon cancer. Langenbeck´s Arch Surg 384 (5): 504, 1999.

Heiss MM, Allgayer H, Babic R, Grützner KU, Schildberg FW: Identification of high risk patients in gastric cancer by specific tumor–associated protease patterns. Langenbeck Arch Surg 384, 1:94, 1999.

Heiss MM, Allgayer H, Grützner KU, Babic R, Jauch KW, Schildberg FW: Erweitertes biologisches Staging durch Mikrometastasen und tumorassoziierte Proteasen beim Magenkarzinom. Acta Chirurgica Austriaca, 31(Suppl 155):7, 1999.

Heiss MM, Simon E, and Allgayer H: Untersuchung zur Expression des Urokinase-typ Plasminogen Aktivator-Rezeptors (uPA-R) auf disseminierten Tumorzellen als Indikator einer klinisch relevanten minimal residualen Tumorkomponente beim Magenkarzinom. Doktorandenkolloquium der Chir. Forschung Freiburg und der Chir. Forschung der LMU München, Proceedings, Freiburg, 1999.

2000

Beyer BCM, Allgayer H, Pietsch AR, Heizmann O, Wustrow TPU, Grützner KU, Schildberg FW, Heiss MM (2000): Tumor-associated proteolysis and prognosis: Validation of the urokinase system in the preoperative staging of gastric cancer. Proc Am Assoc Cancer Res 41:3283, 2000.

Allgayer H, Wang H, Shirasawa T, Sasazuki T, Heiss MM, Schildberg FW, Boyd DD: Inhibition of Urokinase receptor (uPA-R) expression and uPA-R-mediated proteolysis in colon cancer by targeted disruption of the K-ras oncogene. Proc Am Assoc Cancer Res 41:1301, 2000.

Allgayer H, Wang H, Gallick GE, Crabtree A, Heiss MM, Schildberg FW, Boyd DD: Induction of u -PAR expression in colon cancer bySrc via Sp1 transcription factor. ISOBM 2000 Proceedings (From Tumor Biology to Clinical Oncology), Karger (Basel, Freiburg, Paris, London), p. 126, 2000.

Allgayer H, Wang H, Gallick GE, Crabtree A, KrakerAJ, Heiss MM, Schildberg FW, Boyd DD: Transkriptionale Induktion der Expression und Funktion des Urokinase- Rezeptors (u-PAR) beim Colonkarzinom durch das c-src Onkogen via Sp1 – erste Hinweise auf die Inhibition von Src als mögliche anti-metastatische Therapie. Vereinigung der Bayerischen Chirurgen – Wissenschaftliche Referate der 77. Tagung (Hrsg: Jauch KW, Bauer H, Metak G): p. 29, 2000.

Allgayer H, Wang H, Gallick GE, Crabtree A, KrakerAJ, Heiss MM, Schildberg FW, Boyd DD: Transkriptionale Regulation von Urokinase-Rezeptor durch das c-src Onkogen. in: Enders G, Meissner F, Peters J, Messmer K (Hrsg.): Research Festival 2000. P. 22, 2000.

2001

Allgayer H, Boyd DD, Heiss MM, Curley SA, and Gallick GE.: Elevated Src kinase activity in primary colorectal cancer is a new biological indicator of a poor clinical prognosis. Proc Am Assoc Cancer Res 42:577, 2001.

Schewe D, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW, and Allgayer H: Transcription factor binding to region –152/-135 of the urokinase receptor (U-PAR) gene: First analysis of a clinical relevance in gastrointestinal carcinomas. Proc Am Assoc Cancer Res 42: 618, 2001.

Allgayer H, Gallick GE, Wang H, Crabtree A, Kraker AJ, Heiss MM, Schildberg FW, Boyd DD: Transcriptional regulation of urokinase receptor expression in colon cancer by Src via Sp1 – Src inhibition as a potential anti-metastatic therapy? Anticancer Research, Abstracts of the IIAR conferences 2001, vol.21(3A): p. 1625, 2001.

Schewe D, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW, Allgayer H: Bindung von Transkriptionsfaktoren an Region –152/-135 des Urokinase-Rezeptor (u-PAR)-Gens: Erste Analyse einer klinischen Relevanz in gastrointestinalen Karzinomen. Wiss Referate 78. Tagung der Vereinigung der Bayerischen Chirurgen (Hrsg. V. Bühren), Gerhard Metak Verlag, S. 22.

Allgayer H: Gemeinsame Regulatoren von Matrix-Metalloproteinasen und Urokinase- Rezeptor – molekulare Strategien von Tumorzellen zur Erlangung des invasiven Phänotyps. Matrix- Metalloproteinasen- DFG-Workshop Bielefeld, März 2001, Abstractband, S. 7.

Allgayer, H: Molecular regulation of urokinase-receptor (u-PAR) gene expression in colon cancer – potential therapeutic and clinical significance. Proceedings of the 2nd general meeting of the International Proteolysis Society (IPS), Oct. 31st – Nov 4th, Freising, p. L82, 2001.

Allgayer H, Schewe DM, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Beyer BCM, Schildberg FW, Heiss MM: Identification of a subpopulation of gastrointestinal cancer patients with tumor-specific transactivation of u-PAR-gene expression via an AP-2/Sp1 promoter motif. Proceedings, CAMO, Chirurgische Forschungstage Halle/Saale, 2001.

Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, and Allgayer H: Evidence of an independent prognostic relevance of urokinase- receptor expression by disseminated tumor cells in the bone marrow in a large prospective patient series. Proceedings, CAMO, Chirurgische Forschungstage Halle/Saale, 2001.

Allgayer H: Molecular regulation of urokinase-receptor (u-PAR) gene expression as one potential concept for molecular staging and therapy. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001.

Heiss MM, Allgayer H, Grützner KU, Babic R, Schildberg FW: Molecular staging of gastric cancer: Definition of new prognostic subgroups by biological tumor markers. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001.

Gallick GE, Allgayer H, Parikh NU, Herynk M, Minard ME: Signal transduction intermediates as prognostic markers and targets for therapeutic intervention in colorectal carcinoma. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001.

Grützner KU, Pietsch A, Beyer BCM, Allgayer H, Heiss MM, Schildberg FW: Minimal residual disease as a potential staging entity in colorectal cancer. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001.

Schewe DM, Heiss MM, Boyd DD, Wang H, Lengyel E, Hornung HM, Grützner KU, Schildberg FW, Allgayer H: First clinical evidence of tumor-specific transcription factor binding to region –152/-135 of the urokinase-receptor (u-PAR) gene in resected gastrointestinal carcinoma tissues. Proceedings 1st International Congress on Molecular Staging of Cancer, Munich 6-8, 2001.

2002

Leupold JH, Colburn NH, Yang HS, Lengyel E, Schildberg FW, Heiss MM, Allgayer H: First evidence for the new tumor suppressor Pdcd4 as a regulator of u-PAR, an invasion-related gene. Proc Am Assoc Cancer Res 43: 622, 2002.

Allgayer H: Transcriptional regulation of the urokinase-receptor (invited abstract). Proceedings of the ISFP/ IFRS-Meeting, p.38, 2002.

Allgayer H, Boyd DD, Heiss MM, Curley SA, Gallick GE: Erstnachweis der übermässigen Aktivität des Protoonkogen-Produktes Src als neuer und unabhängiger Prognosefaktor in einer Serie colorektaler Karzinome. Proceedings, Chirurgische Arbeitsgemeinschaft für Molekulare Onkologie (CAMO), p. 25-3, 2002.

2003

Leupold JH, Colburn NH, Yang HS, Boyd DD, Lengyel ER, Jauch KW, Allgayer H: Erster Hinweis auf eine Rolle des neu beschriebenenen Tumor –Suppressorgens Pdcd4 als Regulator des Invasionsmoleküls Urokinase Rezeptor. Proc Kongress Deutsche Gesellschaft für Chirurgie 2003.

Biller T, Schewe DM, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, Allgayer H: First ex vivo analysis of AP-1-family members bound to region –190/-171 of the urokinase receptor (u-PAR) gene in a large cancer patient series. Proceedings (1st edition) of the American Association for Cancer Research (AACR), #1944, 2003.

Biller T, Schewe DM, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, Allgayer H: First ex vivo analysis of AP-1-family members bound to region –190/-171 of the urokinase receptor (u-PAR) gene in a large cancer patient series. Proceedings (2nd edition) of the American Association for Cancer Research (AACR), R1944, p. 382, 2003.

Allgayer H: Frau Dr. med. Irmgard Graute-Oppermann - das Leben einer Chirurgischen Pionierin. Deutsche Gesellschaft für Chirurgie – Mitteilungen 3/2003, S. 278. Demeter Verlag (Berlin), 2003.

2004

Schewe DM, Biller T, Leupold JH, Lengyel ER, Schildberg FW, Jauch KW, Allgayer H: Erste in vivo Analyse von Subgruppen mit einer tumor-spezifischen Transkriptionsfaktorbindung an den Urokinase- Rezeptor Promotor (u-PAR) in einer grossen Serie gastrointestinaler Karzinome. Deutsche Gesellschaft für Chirurgie, Proceedings 121. Jahreskongress, 2004.

Fuchs T, Grützner KU, Simon E, Jaeger M, Heiss MM, Schildberg FW, Jauch KW, Allgayer H: Immunocytochemical phenotyping of minimal residual disease— identification of clinically relevant potential therapeutic targets. Proceedings of the American Association for Cancer Research (AACR) 2004, p. 430.

Allgayer H: Regulators of the urokinase-receptor—potential relevance for the clinic and in vivo. Angiogene-sis, vol.7 suppl.1: p.52, 2004.

2005

Maurer GD, Leupold JH, Schewe DM, Biller T, Hornung HM, Grützner KU, Lau- Werner U, Post S, Allgayer H: Induction of urokinase-receptor (u-PAR) gene expression via Src and two different u-PAR- promoter elements: First analysis of in vivo and prognostic relevance in resected colorectal carcinomas. Proceedings of the American Association for Cancer Research (AACR) 2005, abstr. 1268.

Leupold JH, Lengyel ER, Post S, Allgayer H: Src-induced uPAR gene expression is also mediated via an AP-1 motif and is associated with increased invasive capacity in vivo. Proceedings of the American Association for Cancer Research (AACR) 2005, abstr. 4526.

Allgayer H: Molecular regulation of an invasion-related molecule – options for tumor staging and clinical strategies. EACR Proceedings of the ECCO 13-Congress 2005.

2006

Asangani IA, Leupold JH, Gil-Parrado S, Post, S, Allgayer H: Promoter characterization of human small regulatory subunit calpain, CSS1. Proceeding of the American Association for Cancer Research (AACR) 2006, abstract no. 877.

Beyer BCM, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H: Urokinase-system expression in gastric cancer – Confirmation of prognostic impact in an independent patient series and first evidence for a predictor in preoperative biopsies and intestinal metaplasia. Proceedings of the American Association for Cancer Research (AACR) 2006, abstract no. 4366.

Medved F, Grobholz R, Jost C, Mudduluru G, Leupold JH, Schumacher J, Colburn NH, Post S, Allgayer H: Evidence of Pdcd4 as a novel marker for tumor diagnosis and progression in resected colorectal carcinomas. EACR Congress, Budapest, 01.- 04.06.2006.

Allgayer H: Welcome Address: 2nd International Congress on Molecular Staging of Cancer, June 22-26, 2006 in Heidelberg. European Journal of Cancer 4, No. 6, p. 1 Suppl 2006.

Allgayer H: Specific transcriptional regulators of the u-PAR gene – in vivo and clinical relevance, and first suggestions for molecular tumor staging. European Journal of Cancer 4, No. 6, p. 6 Suppl 2006.

Kates R, Allgayer H, Harbeck N: Hierarchical neural net technology for molecular staging with clinical data. European Journal of Cancer 4, No. 6, p. 9 Suppl 2006.

Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H: Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2 -related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. European Journal of Cancer 4, No. 6, p. 28 Suppl 2006.

Leupold JH, Yang H-S, Colburn NH, Boyd DD, Lengyl ER, Post S, Allgayer H: Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (u-PAR) gene expression via Sp-transcription factors. European Journal of Cancer 4, No. 6, p. 28 Suppl 2006.

Medved F, Grobholz R, Jost C, Mudduluru G, Leupold JH, Schumacher J, Colburn NH, Post S, Allgayer H: Evidence of Pdcd4 as a novel marker for tumor diagnosis and progression in resected colorectal carcinomas. European Journal of Cancer 4, No. 6, p. 28-29 Suppl 2006.

Mudduluru G, Post S, Allgayer H: Preliminary promoter characterization of the gene for the human receptor tyorsine kinase AXL. European Journal of Cancer Suppl4, No. 6, 2006.

Asangani IA, Leupold JH, Gil-Parado S, Post S, Allgayer H: Promoter characterization of human small regulatory subunit calpain, CSS1. European Journal of Cancer 4, No. 6, p. 37 Suppl 2006.

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung H-M, Lau-Werner U, Post S, Allgayer H: Transcriptional and molecular regulators of the urokinase- receptor-(u-PAR)-gene: First analysis of independent prognostic relevance in resected colorectal cancer. European Journal of Cancer 4, No. 6, p. 52-53 Suppl 2006.

Bleier S, Laufs S, Sorg U, Kleff V, Flasshove M, Allgayer H, Seeber S, Zeller WJ, Fruehauf S, Moritz T: Clonal analysis of hematopoietic stem cells after serial transplantation of animals receiving MGMTP140K gene transduced cells following chemotherapy. European Society of Gene Therapy 2006, Prag.

Leupold JH, Bach F, Post S, Allgayer H: Essential u-PAR promoter cis-element as a tool for targeting metastatic tumor cells. Langenbecks Arch. Surg 391: 513-543, 2006.

2007

Mudduluru G, Post S, Allgayer H: Sp1 and Sp3 mediate transcription of the human receptor tyrosine kinase AXL Gene. Proceedings of the American Association for Cancer Research, 2007.

Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, Post S, Jansen A, Colburn NH, Allgayer H: Loss of Pdcd4 expression marks adenoma-carcinoma transition and is an independent prognostic factor in colorectal cancer. Proceedings of the American Association for Cancer Research, 2007.

Giordano FA, Appelt J-U, Zimmermann M, Weinhardt S, Wagenblatt A, Allgayer H, Zeller WJ, Fruehauf S, Laufs S: The GTSG.org Database: A first meta-analysis of more than 11.300 retroviral gene therapy vector insertion sites. Submitted to American Society of Gene Therapy, Seattle 2007.

Nikolova, DA, Asangani IA, Rasheed SAK, Harms A, Post S, Manegold C, Allgayer H: Cetuximab attenuates EGF induced u-PAR expression in NSCLC. Eur J Cancer Vol 5, No. 4, 367-368.

Allgayer H: Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Proceedings 6th Annual AACR International Conference “Frontiers in Cancer Prevention Research”, December 5-8, 2007, Philadelphia/USA, pp. 186.

2008

Rasheed S, Efferth T, Post S, Nelson N, Hughes DPM, Mills GB, Allgayer H: Artesunate decreases invasion of non-small cell lung cancer. Proceedings Annual Meeting American Association for Cancer Research, San Diego, April 12-16, 2008, Vol. 49.

Nikolova SA, Asangani I, Rasheed S, Nelson L, Hughes DPM, Mills GB, Post S, Buchholz E, Manegold C, Allgayer H: Cetuximab attenuates EGF induced u-PAR expression: study on the anti-metastatic potential of Cetuximab in NSCLC. Proceedings Annual Meeting American Association for Cancer Research, San Diego, April 12-16, 2008, Vol. 49.

Allgayer H: Molecular markers 2008: defining targeted therapy in non-small-cell lung cancer (NSCLC). 3rd Euroregional Workshop on Thoracic Oncology: Advances in thoracic cancer treatment WCLC 2008 and ASCO 2008 follow-up. Vilnius, Lithuania, June 20-21, 2008.

Rotert JV, Hohenberger P, Leupold JH, Allgayer H: Src activity is increased in liposarcomas and in gastrointestinal stromal tumors – analysis of associations with clinical and molecular tumor characteristics. Eur J Cancer 6(9), 2008.

Leupold JH, Asangani I, Post S, Allgayer H: Characterization of the human programmed cell death protein 4 (pdcd4) promoter. Langenbecks Arch Surg 393:759- 815, 2008.

Körner A, Nikolova D, Mudduluru G, Manegold C, Allgayer H: Enzastaurin inhibits urokinase-receptor (u-PAR) expression in Non-Small Cell Lung Cancer (NSCLC) cells, migration, and invasion. Posterpreis International Thoracic Oncology Congress, Dresden, 01.-05.10.2008.

Kirschner MB, Leupold JH, Schmidt K, Post S, Manegold C, Allgayer H: Zoledronic acid treatment leads to reduced invasion and tumor growth of lung cancer cells. International Thoracic Oncology Congress, Dresden, 01.-05.10.2008.

Nikolova DA, Asangani IA, Nelson LD, Hughes DPM, Siwak D, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H: Cetuximab attenuates invasion,metastasis and u-PAR gene expression in non small cell lung cancer: u-PAR and E-cadherin are novel bio markers of Cetuximab sensitivity. International Thoracic Oncology Congress, Dresden, 01.-05.10.2008.

Bleier S, Maier P, Grund N, Appelt U, Allgayer H, Zeller WJ, Fruehauf S, and Laufs S: Chemoselection: Does it impact integration patterns and clonal size of gammaretrovirally transduced human bone marrow repopulating cells? Deutsche Gesellschaft für Hämatologie und Onkologie, Congress 2008.

Giordano FA, Appelt JU, Grund N, Opelz G, Zeller JW, Allgayer H, Fruehauf S, and Laufs S: The GTSG.org database: A monitoring system for insertion sites of gene therapy vectors used in clinical gene therapy studies. Human Gene Therapy. October 2008, 19(10): 1098-1202.

Grund N, Maier P, Appelt U, Allgayer H, Wenz F, Zeller WJ, Fruehauf S, and Laufs S: Chemo-therapy pressure: its impact on integration site patterns of lentivirally transduced human hematopoietic stem cells. Human Gene Therapy. October 2008, 19(10): 1098-1202.

Laufs S, Giordano FA, Appelt JU, Roeder I, Hotz-Wagenblatt A, Opelz G, Zeller WJ, Allgayer H, and Fruehauf S: Gene therapy vector insertion site analysis and storage tools. International Society for Cellular Therapy Congress 2008.

2009

Allgayer H: Concepts, problems and perspectives of targeted and tailored cancer therapy”. Joint 4th EORTC Pathobiology Group Annual Meeting/1st International Multidisciplinary Cancer Research Congress. Antalya/Turkey, May 21-24, 2009.

Heckmann D, Maier P, Wenz F, Zeller WJ, Fruehauf S, Laufs S, Allgayer H: The role of SDF-1 /CXCR4 axis in migration and invasion of colorectal cancer cells in vitro. Poster DGHO-Meeting, Mannheim, October 2009.

Kabeer Rasheed SA, Efferth T, Asangani I, Allgayer H: Artesunate – first evidence that an anti-malaria drug inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. CESAR Annual Meeting, Heidelberg, October 2009.

Patil N, Schwarzbach M, Laufs S, Allgayer H: Transforming capacity of FUS-CHOP fusion transcripts – Insight in soft tissue liposarcoma. PhD symposium proceedings, DKFZ Heidelberg 2009.

2010

Nelson L, Mannsperger H, Bender C, Buergy D, Kambakamba P, Mudduluru G, Hughes DP, Van Dyke MW, Allgayer H: Triplex DNA-binding proteins in resected normal and tumor tissues from colorectal cancer patients: biological and clinical relevance. Proceedings of the American Association of Cancer Research (AACR) Washington, April 2010.

Mudduluru G, Ceppi P, Regalla K, Allgayer H: Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in cancer cell lines. Proceedings of the American Association of Cancer Research (AACR) Washington, April 2010.

Regalla K, Mudduluru G, Ceppi P, Kozlowski M, Niklinski K, Allgayer H: Mir-30 acts as an anti- metastatic microRNA and is downregulated in non-small cell lung cancer. Proceedings of the American Association of Cancer Research (AACR) Washington, April 2010.

Heckmann D, Maier P, Zucknick M, Giordano F, Wenz F, Zeller WJ, Fruehauf S, Laufs S, Allgayer H: The role of the SDF1 /CXCR4 axis in invasion of colorectal cancer cells. Congress of the European Association of Cancer Research (EACR) Norway, Proceedings, June 2010.

Patil N, Kabeer SA, Schwarzbach M, Laufs S, Allgayer H: First evidence that FUS- CHOP leads to increased invasion and migration via MMPs in liposarcoma. Proceedings of the American Association of Cancer Research (AACR) Washington, April 2010.

Ceppi P, Mudduluru G, Regalla K, Rap I, Scagliotti GV, Papotti M, Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small-cell lung cancer. Proceedings, EORTC Meeting, Amsterdam, 2010.

2011

Udainiya S, Rasheed SAK, Meyer Ch, Leupold JH, Ceppi P, Dooley S, Karunagaran D, Papotti M, Allgayer H: Smad 7 induces invasion, migration and in vivo metastasis in Non-Small Cell lung Cancer. Congress of the American Association of Cancer Research (AACR) Orlando, USA, April 2011.

Patil N, Rasheed SAK, Leupold J, Schwarzbach M, Allgayer H: A mechanistic study on the oncogenic role of FUS-CHOP fusion protein in liposarcoma. Congress of the American Association of Cancer Research (AACR) Orlando, USA, April 2011.

Mudduluru G, Körner A, Manegold C, Fulda S, Allgayer H: Enzastaurin stabilizes p53 and inhibits Axl gene expression and invasion in non-small cell lung cancer (NSCLC). Proceedings of the American Association of Cancer Research (AACR), Orlando, USA, April 2011.

Mudduluru G, Lunavat TR, Scharp M, Muppala S, Patil N, Abba M, Leupold JH, Allgayer H: miR-135b and miR-210 induce invasion, distant metastasis and EMT in colorectal cancer. 5th International EMT meeting in Biopolis, Singapore, 10-13 October 2011.

2012

Mudduluru, G, Lunavat TR, Scharp M, Muppala S, Patil N, Leupold JH, Abba M, Allgayer H: miR-135b and miR-210 induce invasion and distant metastasis by targeting SIAH1 and SETD2 in colorectal cancer. Proceedings of the American Association of Cancer Research (AACR), Washington, USA, April 2012.

Rasheed SAK, Mudduluru G, Patil N, Leupold JH, Efferth T, Allgayer H: Cetuximab and Artesunate synergistically inhibit the invasion and distant metastasis of non-small cell lung cancer. Proceedings of the American Association of Cancer Research (AACR), Washington, USA, April 2012.

Muppala S, Mudduluru G, Leupold LH, Buergy D, Sleeman JP, Allgayer H: CD24 induced miR-21 regulation is mainly mediated through Src, and both (CD24, Src) are post -transcriptionally downregulated by miR-34a. Proceedingsof the American Association of Cancer Research (AACR), Washington, USA, April 2012.

2013

Abba M, Allgayer H: Pilot study comparisons of tumor and metastasis genomes in colorectal cancer. GAP 2013, Houston, USA, 2013.

Batliner J, Abba M, Hauser C, Allgayer H: miR-218 suppresses invasion and migration via inhibition of ZEB2 and N-Cadherin in colon cancer. Proceedings of the American Association of Cancer Research (AACR), Washington, USA, April 2013.

Abba M, Patil N, Rasheed K, Nelson LD, Mudduluru G, Leupold JH, Allgayer H: A direct regulation of Twist1 by FOXQ1 promotes colorectal cancer metastasis. Proceedings of the American Association of Cancer Research (AACR), Washington, USA, April 2013.

Abba M, Allgayer H: Whole genome sequencing identifies metastasis specific copy number variations in colorectal cancer. Proceedings of the American Association of Cancer Research (AACR), Washington, USA, April 2013.

2014

Mudduluru G, Abba M, Batliner J, Patil N, Scharp M, Lunavat TR, Leupold JH, Oleksiuk O, Dilafruz J, Thiele W, Rothley M, Benner A, Ben Neriah Y, Sleeman J, Allgayer H: A systematic approach to the metastatically relevant microRNA landscape. Proceedings of the American Association of Cancer Research (AACR), San Diego, USA, April 2014.

Mudduluru G, Abba A, Batliner J, Patil N, Leupold JH, Thiele W, Rothley M, Benner A, Sleeman J, Allgayer H: A systemic approach to the metastatically relevant microRNA landscape. Proceedings of the Congress of the European Association for Cancer Research (EACR), Munich/Germany, June 2104. Eur J Cancer 2014 pp S146- S147.

Hauser C, Hutter B, Buchhalter I, Shavinskaya A, Abba M, Yadzanparast H, Eils R, Brors B, Allgayer H: Identification of deregulated genes in colorectal cancer metastasis through whole genome and transcriptome sequencing. Proceedings of the Congress of the European Association for Cancer Research (EACR), Munich/Germany, June 2014. Eur J Cancer 2014 pp S103.

Mudduluru G, Abba M, Batliner J, Patil N, Scharp M, Lunavat T, Leupold J, Oleksiuk O, Buchhalter I, Thiele W, Rothley M, Benner A, Sleeman J, Allgayer H: Defining the metastatically relevant microRNA landscape in colorectal cancer. Proceedings of the International RNA Conference, 22. – 25.06.2014, in Heidelberg, 2014.

Mudduluru G, Abba M, Batliner J, Patil N, Scharp M, Lunavat T, Leupold J, Oleksiuk O, Buchhalter I, Thiele W, Rothley M, Benner A, Sleeman J, Allgayer H: A systematic approach to the metastatically relevant microRNA landscape. Proceedings of the 15th biennial Metastasis Research Congress, Heidelberg, Juni 28 – July 1, 2014.

Leupold JH, Jungmann A, Müller OJ, Allgayer H: Development of AAV expression cassettes for colorectal cancer-targeted cytotoxic gene therapy. Proceedings,18. Chirurgische Forschungstage, Hannover, 09.-11.10.2014.

2015

Oleksiuk O*, Abba M* (* shared first authors), Tezcan K, Schauffler W, Patil N, Bestvater F, Altevogt HP, Cremer C, Allgayer H: Subcellular distribution of miR-31 in metastatic and non-metastatic colorectal cancer cell lines by Super-resolution Single- molecule Localization microscopy. Proceedings of the American Association of Cancer Research (AACR), Philadelphia, 2015.

Allgayer H: A Translational Approach to the Metastatically Relevant MicroRNS- Landscape. Cancer Microenvironment (2015) 8 (Suppl 1):S1 – S141.

Laudato S, Patil N, Leupold JH, Abba M, Ben-Neriah Y, Allgayer H: Tumor Suppressive microRNA-30 inhibits cancer cell migration, invasion and adhesion to ECM by regulating Intergrins. Eur Surg Res 2015, 11:198-289.

Laudato S, Patil N, Leupold JH, Abba M, Ben-Neriah Y, Allgayer H: Tumor Suppressive role of p53-induced microRNS-30e in colorectal cancer progression. The Fourteenth Annual KI Cancer Retreat, Djurönäset, September 28-29, 2015.

2016

Laudato S, Patil N, Leupold JH, Abba M, Ben-Neriah Y, Allgayer H: p43-regulated microRNA-30 inhibits cancer cell migration, invasion, adhesion and metastasis by regulating Integrins. Proceedings of the AACR Annual Meeting, New Orleans, USA 2016.

2017

Zhou C, Abba M, Benner A, Allgayer H: Aberrant miRNA CpG methylation orchestrates colorectal cancer progression and metastasis. Proceedings 21 Chirurgische Forschungstage, Köln, 21-23.09.2017.

2018

Allgayer H: The genomic landscape characterizing metastasis. 8th International Conference On Tumor Microenvironment: Progression, Therapy & Prevention, Lissabon, presentation. June 10-14, 2018.

Allgayer H: Die akademische Freiheit bei der interdisziplinären Entwicklung zielgerichteter Therapeutika in der Personalisierten Medizin. Alfried Krupp von Bohlen und Halbach-Stiftung: Preisträger-Kolloquium 2018- Forschungsfreiheit und Forschungsförderung, Essen, November 22-23, 2018.

Marongiu L and Allgayer H: Simulated sequences mimicking integration designed to test virus integration tools, Proceedings, 22. Chirurgische Forschungstage, Erlangen, 06-08.09.2018.

Allgayer H: Novel insights into metastasis evolution and hypotheses for colorectal cancer therapy by whole genome sequencing. Sign Gene Symposium on Cell Motility and Metastasis, Usedom, September 3- 5, 2018.

Allgayer H: Defining key players of cancer metastasis. 68th Lindau Nobel Laureate Meeting dedicated to Physiology and Medicine, Lindau, June 29th 2018.

2019

Hohenberger P, Tu L, Zhao W, Wang MW, Zhang Z, Allgayer H, Cao H. Abstract 758: Long non-coding RNAH19 as a competing endogenous RNA of KIT in the progression of GIST. Cancer Res. July 1 2019 (79) (13 Supplement) 758; DOI: 10.1158/1538-7445.AM2019-758.

Allgayer H. Abstract 180: Defining the metastasome in colorectal cancer: Novel hypotheses on tumor progression, metastasis evolution and therapy by whole genome sequencing. Cancer Res. July 1 2019 (79) (13 Supplement) 180; DOI: 10.1158/1538- 7445.AM2019-180.

Abdelrahim O, Patil N, Leupold JH, and Allgayer H. MiR-494-5p inhibits cell proliferation, invasion and migration in colorectal cancer through targeting JAK1. 23. Chirurgische Forschungstage. Aachen, 12.09.-14.09.2019.

Marongiu L and Allgayer H. Simulated datasets for testing virus integration. Global Summit on Microbiology and Virology. Prague, Czech Republic. March 2019.

Context Column